Based on the cell free nucleic acid analysis information of blood samples, the results of microbiome and metabolite analysis of stool and urine samples of pancreatic cancer and bile duct cancer patients, the clinical correlations of them with primary cancer are evaluated. And based on these information, biomarkers for diagnosis, treatment, and prognosis of pancreatic and bile duct cancer are explored.

Inclusion Criteria:

• Patients diagnosed with pancreatic cancer through histological or radiologic examination and before treatment begins
• Patients diagnosed with biliary tract cancer (cholangiocarcinoma, gallbladder cancer) through histological or radiologic examination and before treatment begins
• Patients aged 18 or older who voluntarily agrees to participate in the study and is willing to understand and comply with the subsequent treatment procedures and sample collection schedule

Exclusion Criteria:

• Where the subject himself/herself refuses to fill out the consent form or is unable to fill out the consent form

• In the case where the sample storage conditions suggested by the reagent manufacturer are not satisfied

• Only samples that can cause errors when determining results are acquired:

  • Heat treated specimen

    • Incompletely coagulated serum and bacterial samples ③ Samples with particulate matter elements (e.g., fibroblasts, red blood cells) remaining in the sample

      ④ Specimens previously frozen and stored with blood clots that have confirmed an increase in non-specific reactivity in which samples appear to have denatured during storage

      ⑤ Sample from deceased patient

      ⑥ A patient specimen with a malignancy of ohter site

      ⑦ Sample from vulnerable persons such as pregnant women, minors, etc

Patients aged 18 or older, who diagnosed with pancreatic cancer or biliary tract cancer (cholangiocarcinoma, gallbladder cancer) through histological or radiologic examination and before treatment begins